Latest therapeutic novelties and patents in pulmonary hypertension

Recent Patents on Cardiovascular Drug Discovery

Volumn 6, Issue 1, 2011, Pages 55-60

  Hardavella, Georgia F ^a   Dionellis, Georgios S ^a   Kantza, Christina G ^b   Koulouris, Nikolaos G ^a   Alchanatis, Manos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Hospital for Diseases of the Chest SOTIRIA   (Greece)

Author keywords

Developments; Patents; Pulmonary arterial hypertension; Therapeutic advances; Therapeutic novelties

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; AMBRISENTAN; AZAINDOLE 1; BOSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ERLOTINIB; FASUDIL; GEFITINIB; ILOPROST; IMIDAZOLE DERIVATIVE; LAPATINIB; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTANOID; RAPAMYCIN; RHO KINASE INHIBITOR; RIOCIGUAT; SELEXIPAG; SILDENAFIL; SIMVASTATIN; SITAXSENTAN; SORAFENIB; SULFONAMIDE; SULFONYLUREA DERIVATIVE; TADALAFIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIPROST; VARDENAFIL;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CHINESE MEDICINE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUGS, INVESTIGATIONAL; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION, PULMONARY; PATENTS AS TOPIC; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 79551672222     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489011794578491     Document Type: Article

References (31)

1. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT), Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34(6):1219-1263.
2. Taichman D, Mandel J. Epidemiology of pulmonary arterial hypertension. Clin Chest Med 2007; 28(1) doi: 10.1016/j.ccm.2006.11.012.
3. Rhodes CJ, Davidson A, Gibbs JS, Wharton J, Wilkins MR. Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther 2009; 121(1): 69-88.
4. Anderson JR, Nawarskas JJ. Pharmacotherapeutic management of pulmonary arterial hypertension. Cardiol Rev 2010; 18(3):148-162.
5. Archer S, Michelakis E. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med 2009; 361:1864-1871.
6. Galie N, Brundage B, Chofrani H, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
7. Zhao L, Sebkhi A, Ali O, Wojciak-Stothard B, Mamanova L, Yang Q, et al. Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur Respir J 2009; 34: 948-957.
8. Stenmark KR, McMurtry IF. Vascular remodelling versus vasoconstriction in chronic hypoxic pulmonary hypertension: a time for reappraisal? Circ Res 2005; 97: 95-98.
9. McCoon M, Frost A, Oudiz R, Badesch DB, Galie N, Olschewski H, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009; 135: 122-129.
10. Health Canada. Drugs and Health products. Available at http://www.hc-sc.gc.ca/dhp-mps/medeff/advisoriesavis/public/_2010/thelin_2_pc-cp-eng.php (Accessed on January 03 2011).
11. Oudiz RJ, Galie N, Olschewski H, Torres F, Frost A, Ghofrani HA, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: 1971-1981.
12. McLaughlin V, Benza R, Rubin L, Channick RN, Voswinckel R, Tapson VF, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial. J Am Coll Cardiol 2010; 55(18):1915-1922.
13. Mouchaers KTB, Schalij I, de Boer MA, Postmus PE, van Hinsbergh VWM, van Nieuw GP, et al. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: Comparison with bosentan and sildenafil. Eur Respir J 2010; 36(4): 800-807.
14. Dahal BK, Kosanovic D, Pamarthi PK, Sydykov A, Lai Y-J, Kast R, et al. Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. Eur Respir J 2010; 36(4): 808-818.
15. Hoeper M, Gall H, Seyfarth H, Halank M, Ghofrani HA, Winkler J, et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J 2009; 34: 132-137.
16. Ferreira A, Shenoy V, Yamazato Y, Srinivas S, Joseph F, Lihui Y, et al. Evidence for angiotensine-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Resp Crit Care Med 2009; 179:1048-1054.
17. Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, Bölkow D, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009; 33: 785-792.
18. Ghofrani HA, Hoeper MM, Halank M, Meyer FJ, Staehler G, Behr J, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: A phase II study. Eur Respir J 2010; 36 (4): 792-799.
19. Dahal BK, Cornitescu T, Tretyn A, Pullamsetti SS, Kosanovic D, Dumitrascu R, et al. Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am J Resp Crit Care Med 2010; 181: 158-167.
20. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, et al. Pulmonary arterial hypertension: Baseline characteristics from the REVEAL Registry. Chest 2010; 137(2): 376-387.
21. Simonneau G, Lang I, Torbicki A, Hoeper MM, Delcroix M, Karlocai K, et al. Efficacy, Safety And Tolerability Of ACT- 293987, A novel oral, non-prostanoid, prostaglandin I2 (IP) receptor agonist: Results from a phase IIa study in pulmonary arterial hypertension (PAH) American Thoracic Society International Conference 2010, New Orleans, USA. Am J Respir Crit Care Med 2010; 181(1): A2515.
22. Najarian, T., Tam, P., Wilson, L. Craig, P. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors. EP2167099A2 (2010).
23. Zhao, Y.Y., Malik, A. Compositions and methods for treating pulmonary hypertension. WO2010152453 (2010).
24. White, J., Taubman, M. Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway. EP1799243 (2010).
25. Southard, G., Southard, J. Sequence modified calcitonin gene related peptides. WO2009142727 (2009).
26. Sandner, P., Tinel, H., Huetter, J., Riedl, B., Klein, M. Diaryl urea for treating pulmonary hypertension. US20100035888 (2010).
27. Pacaud, P., Loirand, G., Derkinderen, M., Agard, C. 5'-Adenosine monophosphate activated protein kinase (AMPK) activators for treating pulmonary hypertension. WO2010103040 (2010).
28. Roberts JD, Polaner DM, Lang P. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992; 340: 818-819.
29. Fullerton DA, Agrafojo J, McIntyre RC Jr. Pulmonary vascular smooth muscle relaxation by cAMP-mediated pathways. J Surg Res 1996; 61: 444-448.
30. Desai, N., Soon-Shiong, P. Methods and compositions for treating pulmonary hypertension. EP2146707 (2010).
31. Hebey Yiling H, Pharmaceutical RE. Methods and compositions for treating pulmonary hypertension. CN11632727A (2010).